Alumis says Phase 2b LUMUS trial of envudeucitinib in systemic lupus erythematosus misses primary endpoint

Management reiterated plans to file an NDA for envudeucitinib in moderate-to-severe plaque psoriasis in 4Q 2026.

Alumis reported topline results from its Phase 2b LUMUS trial of envudeucitinib in moderate-to-severe systemic lupus erythematosus.

• The study missed its main and key secondary goals in the overall patient population, weakening broad-label prospects in SLE.
• A prespecified high-interferon subgroup showed clear clinical benefit, supporting plans for Phase 3 regulatory discussions focused on that segment.
• The drug was generally well tolerated with no new safety concerns flagged.